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RETROSPECTIVE REVIEW OF THE USE OF PALIFERMIN TO PREVENT
MUCOSITIS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION
PATIENTS CONDITIONED WITH HIGH-DOSE CHEMOTHERAPY AND
TOTAL BODY IRRADIATION
Kennedy, D., Gigue`re, P., Corman, C., Hopkins, H. The OttawaHospital,
Ottawa, ON, Canada
Rationale: Mucositis is caused by chemotherapy and radiation and
is characterized by pain, erythema, and ulceration of the oral
mucosa. Palifermin is a keratinocyte growth factor approved for
the prevention of mucositis. The primary objective of this study
was to compare the proportion, duration, and severity of mucositis
in bone marrow transplant patients pre- and post-palifermin
treatment.
Methods: Data were collected retrospectively by a chart review on
patients who received high-dose chemotherapy and total body irra-
diation from January 2004 to February 2009 at The Ottawa Hospi-
tal. Results were analyzed before and after the introduction of
palifermin in August 2006. The severity of mucositis was assessed us-
ing the Bearman scale.
Results: Data were collected from 75 patient charts; 34 of which
received palifermin. The proportion of patients experiencing mu-
cositis was 97.6% for those who did not receive palifermin and
79.4% for those who received palifermin (p5 0.02). Bearman
scale grade$ 2 mucositis was experienced by 92.7% of patients
without palifermin compared to 47.1% with palifermin
(p\0.001). Palifermin reduced the median duration of mucositis
by 4.0 days (p5 0.009).
Conclusion: Palifermin reduced the proportion, severity, and dura-
tion of mucositis in this patient population.438
ELECTRONICAUTOMATIONOFTRANSPLANTCONDITIONINGPROTOCOLS
IN A PEDIATRIC BLOOD AND MARROW TRANSPLANT SERVICE
Wright, F.A.1, Trickett, A.E.2,3, O’Brien, T.A.1 1Centre for Children’s
Cancer and Blood Disorders Sydney Children’s Hospital, Randwick,
NSW, Australia; 2New South Wales Health, Sydney, NSW, Australia;
3University of New South Wales, Sydney, NSW, Australia
Currently there is no commercially available electronic automated
system for the prescribing of conditioning regimens for hematopoi-
etic progenitor cell transplants (HPC). To address this, with the aim
of improving patient safety and reducing prescriber errors, the BMT
Network NSW and the transplant program at Sydney Children’s
Hospital collaborated to develop electronic templates for 15 condi-
tioning regimens.
The Transplant Pharmacist and BMT Network Quality Man-
ager utilized Excel software to generate templates based on cur-
rent approved protocols which contain dropdown lists and
locked formulas. Drug doses are automatically calculated and
incorporate dose rounding according to the patient’s height,
weight and/or age. Donor and recipient transplant characteris-
tics, including HPC cell source and processing, and infectious
disease screening, automatically determine the majority of pro-
phylactic and supportive care. Each template was independently
validated by the Transplant Director to ensure that all formula
function correctly. Templates were then authorised, document
controlled and given a unique document identifier and version
number. Each template is password protected, locked and can-
not be changed without authorisation from the Transplant
Director.
When required for use, the appropriate conditioning regimen
template is selected and patient and donor parameters entered.
Non-automated supportive care (for example blood-product support
and choice of antifungal prophylaxis) can be selected from drop
down boxes. Once complete, the protocol is converted to Acrobat
pdf format, checked and signed by the Transplant Director and
Pharmacist then distributed. The signatures are password protected
and e-stamped with the time and date. No protocol once converted
to Acrobat can be changed.
Previously the preparation of a conditioning protocol was
a lengthy process with manual data collection and entry into
a Word document with multiple opportunities for prescriber er-ror. The development of electronic automated templates has im-
proved efficiency, reduced pharmacy and physician time
dedicated to this task, and in addition has reduced prescriber er-
ror and improved patient safety. This system could be easily
modified to incorporate site-specific rules at other transplant
centres.439
PLERIXA FOR DOSING AND ADMINISTRATION IN A PATIENT WITH
DIALYSIS DEPENDENT RENAL FAILURE
Gregory, K.M.1, Rao, K.V.1, Armistead, P.M.2,3, Shea, T.C.2,3 1Univer-
sity of North Carolina Hospitals, Chapel Hill, NC; 2University of North
Carolina Hospitals, Chapel Hill, NC; 3University of North Carolina,
Chapel Hill, NC
Background: Plerixafor, a CXCR4 antagonist, is approved for stem
cell mobilization for patients undergoing autologous stem cell trans-
plantation, and is useful in the mobilization of patients who have
failed mobilization previously. The approved dosing recommends
a dose adjustment for mild to moderate renal impairment, but no
specific details on dosing in dialysis patients.
Objective:To describe the first reported U.S. experience with use of
plerixafor in dialysis dependent renal failure.
Methods: A 38 year old patient with ISS stage 3 multiple myeloma
was evaluated in our outpatient stem cell transplantation clinic.
The patient had developed renal failure secondary to his myeloma
with a baseline glomerular filtration rate of less than 20 ml/min.
Standard filgrastim-based mobilization was unsuccessful with the
patient’s maximum pre-pheresis CD34+5 5.6 cells/mL. Based on
limited data from Europe, and evaluation of the pharmacokinetic
properties of plerixafor, the patient was treated with G-CSF
(10ug/kg/day) for 4 days and a post-dialysis dose of plerixafor at
a dose of 160 mcg/kg on the evening of day 4, followed by stem
cell collection 12 hours later on Day 5. Dialysis was held during
the attempted mobilization, to avoid removal of plerixafor by ultra-
filtration.
Results: Adequate stem cell yield was obtained with a single dose
of plerixafor in this patient. The morning after initial plerixafor
dosing, the patient’s pre-pheresis CD34+5 125.62 cells/mL.
The patient underwent successful stem cell collection with a yield
of 5.33106 CD34+ cells/kg after his first apheresis session.
Discussion: Based upon our experience with plerixafor in a dialysis-
dependent patient, we are instituting a policy to dose plerixafor at
typical renal adjustment doses, with dialysis sessions being scheduled
prior to plerixafor administration, and repeated, as clinically neces-
sary, after apheresis and prior to the subsequent plerixafor dose. If
clinically feasible, we would recommend avoiding dialysis during
the days required to collect stem cells, although in our single patient
experience, this was not necessary.440
CONTINUOUS INFUSION (CI) CYCLOSPORINE (CSA): ASSESSMENT OF
DOSING IN PEDIATRIC AND ADOLESCENT PATIENTS (PTS) WITH
WEIGHT. 50 KG DURING HEMATOPOIETIC STEM CELL TRANSPLANTA-
TION (HSCT)
Shinkle, M.1, Duerst, R.1,2 1Children’s Memorial Hospital, Chicago, IL;
2Northwestern University, Feinberg School of Medicine, Chicago, IL
Continuous Infusion CsA (5 mg/kg/day) is used for GVHD pro-
phylaxis at Children’s Memorial Hospital (CMH) following full in-
tensity conditioning allogeneic HSCT. Toxicities from CsA are
common and require careful monitoring. A drug utilization evalu-
ation was conducted assessing CI CsA to determine the following
parameters: dose adjustments, drug levels, and toxicities. This ret-
rospective analysis for the drug evaluation report was generated
from the electronic medication entry system (EPIC). Medication
codes for intravenous CsA were used to obtain data on those pts
who received CI CsA. Patient weight, initial CI CsA dose, time
CsA was initiated, measured levels of CsA, and time and amount
of dosage changes were analyzed. From June 2007 through
